By Nancy Lapid (Reuters) – The following are summaries of some of the cancer research advances being presented the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Amgen drug extends survival for some advanced colon cancers Amgen Inc’s drug Vectibix led to “the longest survival ever reported” in a major trial for patients with inoperable advanced cancer originating on the left side of the colon whose tumors did not have RAS gene mutations, researchers reported on Sunday at ASCO 2022 https://meetings.asco.org/2022-asco-annual-meeting/14416?presentation=208990#20899…